Heinig and colleagues, using the Eμ-Tcl1 mouse model of chronic lymphocytic leukemia (CLL), shed light on the trafficking routes of CLL cells into the protective microenvironmental niches in secondary lymphoid organs. The authors propose a crucial role of the resident follicular dendritic cells for leukemia pathogenesis that is essentially orchestrated by the chemokine receptor CXCR5.

Few reports have described the coincidence of chronic lymphocytic leukemia (CLL) and HIV. We administered bendamustine to an HIV-positive refractory CLL patient and obtained a significant objective response. Our results indicate that bendamustine can be used in HIV-infected CLL patients. We also reviewed 12 cases of CLL with HIV infection.

Sequencing studies have been instrumental in understanding the genetic basis of chronic lymphocytic leukemia (CLL). Our recent whole-genome sequencing study focusing on lower cytogenetic risk CLL demonstrated that CLL mutations can be attributed to 3 key mutational processes-2 types of activation induced-cytidine deaminase (AID) signatures and an aging signature-that operate at different times ...

Transformation of chronic lymphocytic leukemia to acute lymphoblastic leukemia is extremely rare. We describe an elderly patient whose lymphocytes on presentation were morphologically characteristic of chronic lymphocytic leukemia, but changed to lymphoblasts in a very short interval. Peripheral blood mononuclear cells were tested for surface immunoglobulins and T65 antigen at initial presentat...

Background: Chronic Lymphocytic Leukemia (CLL) is a heterogeneous disorder with respect to its clinical course. Accurate identification of prognostic factors is becoming increasingly important in order to determine those patients requiring aggressive treatments. The Rai clinical staging systems is used to define disease extent and predict survival. Aim: to evaluate prognostic significance of CD...

We compared the effect of adenosine and adenosine analogues on the phytohemagglutinin-induced proliferative response of blood lymphocytes from normal subjects and patients with chronic lymphocytic leukemia. As measured by the inhibition of thymidine or leucine incorporation, adenosine was more toxic to chronic lymphocytic leukemia (CLL) than to normal lymphocytes. This difference was not affect...

et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chron...

Introduction: Targeted therapies have dramatically changed the treatment landscape of chronic lymphocytic leukemia (CLL). Current paradigms include combinations with small molecules (Bruton tyrosine kinase and B-cell lymphoma 2 inhibitors), chemotherapy, anti-CD20 monoclonal antibodies. Although chemotherapy-free regimens, such as single-agent venetoclax + rituximab, shown efficacy in heavily p...

Chronic lymphocytic leukemia (CLL) remains an incurable disease, with all patients who require therapy destined to relapse and understanding of the pathophysiology of chronic lymphocytic leukemia has advanced significantly. It is now clear that chronic lymphocytic leukemia is a relatively proliferative disorder that requires the help of its microenvironment to be maintained and to progress. The...

Chronic lymphocytic leukemia (CLL) is a common leukemia in adults, but its pathogenesis is still poorly understood. Interleukin-9 (IL-9) is initially described as a growth factor secreted by helper T cells. Recently, the oncogenic activities of IL-9 were reported in some leukemia but not chronic lymphocytic leukemia (CLL). The purpose of the present study is to investigate the expression of IL-...